Biblio Discovery — Demo Discovery Service

4 results for "Raether, Brian"

Showing 1–4 · 3.87 seconds · RSS

  1. Journal Article Full text

    Characterization of the parB-Like yyaA Gene of Bacillus subtilis

    Sievers, Jörg; Raether, Brian; Perego, Marta et al.

    J Bacteriol · 2002 · English · PubMed Central

    We have characterized the yyaA gene of Bacillus subtilis, located near the origin of chromosome replication (oriC). Its protein product is similar to the Spo0J protein, which belongs to the ParB family of chromosome- and plasmid-partitioning proteins. Insertional inactivation of the yyaA gene had…

  2. Journal Article Full text

    Effect of Food Consumption on the Pharmacokinetics of ACP‐204, a Novel 5‐HT(2A) Receptor Selective Antagonist/Inverse Agonist

    Darwish, Mona; Dirks, Bryan; Feng, Xiaoshu et al.

    Alzheimers Dement · 2025 · English · PubMed Central

    BACKGROUND: ACP‐204 is an investigational drug with selective inverse agonism/antagonism of 5‐HT(2A) receptors. Food‐drug interactions can alter the pharmacokinetics (PK) and pharmacodynamics of drugs, impacting their therapeutic efficacy and safety. This study evaluated the effect of concomitant…

  3. Journal Article Full text

    Pharmacokinetics in Healthy Adult and Elderly Patients of ACP‐204, a Novel 5‐HT(2A) Receptor Selective Antagonist/Inverse Agonist

    Darwish, Mona; Feng, Xiaoshu; Dirks, Bryan et al.

    Alzheimers Dement · 2025 · English · PubMed Central

    BACKGROUND: ACP‐204, a potent inverse agonist/antagonist of 5‐HT(2A) receptors, is under investigation for the treatment of Alzheimer’s disease psychosis (ADP). Frail elderly patients with ADP are vulnerable to adverse effects of antipsychotics and potential age‐related differences in drug…

  4. Journal Article Full text

    Analyzing the Effect of ACP‐204 on the QTc Interval in Healthy Adult Participants Using Phase 1 Study Data

    Darwish, Mona; Mason, Jay W; Stanworth, Stephanie W et al.

    Alzheimers Dement · 2025 · English · PubMed Central

    BACKGROUND: QT interval prolongation is a known adverse event of many psychotropic medications. ACP‐204, a potent and selective inverse agonist/antagonist of serotonin 2A (5‐HT(2A)), was developed for the treatment of Alzheimer’s disease psychosis to have an improved pharmacological profile and…